Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
- PMID: 9527161
- PMCID: PMC2170011
- DOI: 10.1136/jnnp.64.3.402
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
Abstract
The neurofilament protein is a major structural protein of neurons and a marker for axonal damage. The concentrations of the light subunit of the neurofilament triplet protein (NFL) in CSF were significantly increased in patients with relapsing-remitting multiple sclerosis compared with healthy controls (p<0.001). Seventy eight per cent of patients with multiple sclerosis showed increased NFL concentrations. Significant correlations between the NFL concentration in CSF and clinical indices were discerned for disability, exacerbation rate, and time from the start of the previous exacerbation to the time of the lumbar puncture. The results suggest that axonal damage occurs during relapsing-remitting multiple sclerosis and that the damage contributes to disability and the appearance of clinical exacerbations. The concentration of NFL in CSF is a potential marker of disease activity in multiple sclerosis and might be useful in future clinical trials of multiple sclerosis.
Similar articles
-
Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.Eur J Neurol. 2015 Aug;22(8):1169-75. doi: 10.1111/ene.12579. Epub 2014 Oct 17. Eur J Neurol. 2015. PMID: 25324032
-
Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.Hell J Nucl Med. 2019 Sep-Dec;22 Suppl 2:113-121. Hell J Nucl Med. 2019. PMID: 31802051
-
Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1059-1067. doi: 10.1136/jnnp-2018-319190. Epub 2019 May 23. J Neurol Neurosurg Psychiatry. 2019. PMID: 31123141 Free PMC article.
-
Neurofilament light chain in the assessment of patients with multiple sclerosis.Arq Neuropsiquiatr. 2019 Jul 15;77(6):436-441. doi: 10.1590/0004-282X20190060. Arq Neuropsiquiatr. 2019. PMID: 31314847 Review.
-
Neurofilaments as biomarkers in multiple sclerosis.Mult Scler. 2012 May;18(5):552-6. doi: 10.1177/1352458512443092. Epub 2012 Apr 4. Mult Scler. 2012. PMID: 22492131 Review.
Cited by
-
Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis.Front Neurol. 2024 Feb 14;15:1354431. doi: 10.3389/fneur.2024.1354431. eCollection 2024. Front Neurol. 2024. PMID: 38426169 Free PMC article.
-
Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt-Jakob disease.Alzheimers Dement (Amst). 2024 Feb 13;16(1):e12548. doi: 10.1002/dad2.12548. eCollection 2024 Jan-Mar. Alzheimers Dement (Amst). 2024. PMID: 38352040 Free PMC article.
-
Normative Values for Serum Neurofilament Light Chain in US Adults.J Clin Neurol. 2024 Jan;20(1):46-49. doi: 10.3988/jcn.2022.0340. J Clin Neurol. 2024. PMID: 38179631 Free PMC article.
-
The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies.Res Sq [Preprint]. 2023 Nov 29:rs.3.rs-3659922. doi: 10.21203/rs.3.rs-3659922/v1. Res Sq. 2023. PMID: 38077014 Free PMC article. Preprint.
-
Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.Neurology. 2023 Nov 7;101(19):e1873-e1883. doi: 10.1212/WNL.0000000000207791. Epub 2023 Sep 25. Neurology. 2023. PMID: 37748882
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical